Amicus Therapeutics Stock Price, News & Analysis (NASDAQ:FOLD)

$15.24 +0.16 (+1.06 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$15.24
Today's Range$14.75 - $15.56
52-Week Range$5.87 - $17.40
Volume3.35 million shs
Average Volume3.77 million shs
Market Capitalization$2.56 billion
P/E Ratio-8.33
Dividend YieldN/A
Beta1.45

About Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics logoAmicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:FOLD
CUSIP03152W10
Phone+1-609-6622000

Debt

Debt-to-Equity Ratio0.39%
Current Ratio6.32%
Quick Ratio6.22%

Price-To-Earnings

Trailing P/E Ratio-8.32786885245902
Forward P/E Ratio-10.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.96 million
Price / Sales567.97
Cash FlowN/A
Price / CashN/A
Book Value$2.52 per share
Price / Book6.05

Profitability

Trailing EPS($1.83)
Net Income$-200,040,000.00
Net Margins-1,092.37%
Return on Equity-63.54%
Return on Assets-23.46%

Miscellaneous

Employees263
Outstanding Shares184,850,000

Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.10. The biopharmaceutical company had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The company's quarterly revenue was up 419.0% on a year-over-year basis. During the same period last year, the business earned ($0.33) EPS. View Amicus Therapeutics' Earnings History.

When will Amicus Therapeutics make its next earnings announcement?

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Amicus Therapeutics.

Where is Amicus Therapeutics' stock going? Where will Amicus Therapeutics' stock price be in 2018?

7 Wall Street analysts have issued 1 year price targets for Amicus Therapeutics' shares. Their predictions range from $15.00 to $24.00. On average, they expect Amicus Therapeutics' share price to reach $19.50 in the next twelve months. View Analyst Ratings for Amicus Therapeutics.

What are Wall Street analysts saying about Amicus Therapeutics stock?

Here are some recent quotes from research analysts about Amicus Therapeutics stock:

  • 1. According to Zacks Investment Research, "AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. " (2/22/2018)
  • 2. Cowen Inc analysts commented, "This morning, FOLD announced that after more recent FDA talks and written." (7/11/2017)

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 27,464,314 shares, a decline of 7.6% from the January 12th total of 29,723,183 shares. Based on an average daily volume of 3,192,320 shares, the short-interest ratio is currently 8.6 days. Currently, 17.0% of the shares of the company are sold short.

Who are some of Amicus Therapeutics' key competitors?

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the folowing people:

  • John F. Crowley J.D., Chairman of the Board, Chief Executive Officer (Age 50)
  • Bradley L. Campbell, President, Chief Operating Officer (Age 41)
  • William D. Baird III, Chief Financial Officer (Age 45)
  • Daphne E. Quimi, Senior Vice President - Finance and Administration, Corporate Controller (Age 51)
  • Kurt J. W. Andrews, Senior Vice President - Human Resources (Age 48)
  • Hung Viet Do, Chief Scientific Officer (Age 49)
  • Ellen S. Rosenberg, General Counsel and Corporate Secretary (Age 54)
  • Jay A. Barth M.D., Chief Medical Officer (Age 53)
  • Donald J. Hayden Jr., Lead Independent Director (Age 61)
  • Robert A. Essner, Independent Director (Age 70)

Who owns Amicus Therapeutics stock?

Amicus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.25%), PRUDENTIAL FINANCIAL INC (6.20%), Redmile Group LLC (6.03%), Jennison Associates LLC (5.84%), Palo Alto Investors LLC (3.61%) and Franklin Resources Inc. (2.24%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Life Sciences Maste Perceptive, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

Who sold Amicus Therapeutics stock? Who is selling Amicus Therapeutics stock?

Amicus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Palo Alto Investors LLC, Redmile Group LLC, Deutsche Bank AG, Alliancebernstein L.P., Jennison Associates LLC, Guggenheim Capital LLC and Metropolitan Life Insurance Co. NY. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.

Who bought Amicus Therapeutics stock? Who is buying Amicus Therapeutics stock?

Amicus Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Millennium Management LLC, Sphera Funds Management LTD., Sectoral Asset Management Inc, Franklin Resources Inc., BlackRock Inc., Tekla Capital Management LLC and Spark Investment Management LLC. Company insiders that have bought Amicus Therapeutics stock in the last two years include Ellen Rosenberg, John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.

How do I buy Amicus Therapeutics stock?

Shares of Amicus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of Amicus Therapeutics stock can currently be purchased for approximately $15.24.

How big of a company is Amicus Therapeutics?

Amicus Therapeutics has a market capitalization of $2.56 billion and generates $4.96 million in revenue each year. The biopharmaceutical company earns $-200,040,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Amicus Therapeutics employs 263 workers across the globe.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedarbrook Dr, CRANBURY, NJ 08512-3618, United States. The biopharmaceutical company can be reached via phone at +1-609-6622000 or via email at [email protected]


MarketBeat Community Rating for Amicus Therapeutics (FOLD)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  295 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  464
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amicus Therapeutics (NASDAQ:FOLD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.863.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.50$18.64$18.07$14.58
Price Target Upside: 17.75% upside20.20% upside13.09% upside21.02% upside

Amicus Therapeutics (NASDAQ:FOLD) Consensus Price Target History

Price Target History for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018Leerink SwannBoost Price TargetOutperform -> Outperform$20.00 -> $24.00HighView Rating Details
2/7/2018Robert W. BairdSet Price TargetBuy$20.00HighView Rating Details
1/10/2018CowenReiterated RatingBuy$22.00MediumView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral -> Neutral$17.00N/AView Rating Details
10/5/2017Chardan CapitalReiterated RatingBuy$16.50 -> $18.50N/AView Rating Details
10/4/2017JPMorgan Chase & Co.Reiterated RatingOverweightN/AView Rating Details
10/4/2017Bank of AmericaBoost Price TargetBuy$15.00 -> $20.00HighView Rating Details
3/8/2016Janney Montgomery ScottUpgradeNeutral -> Buy$10.00 -> $12.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Amicus Therapeutics (NASDAQ:FOLD) Earnings History and Estimates Chart

Earnings by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ FOLD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.29)N/AView Earnings Details
11/8/2017Q3 2017($0.31)($0.41)$9.02 million$10.90 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.37)($0.34)$6.96 million$7.16 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.37)($0.39)$4.16 million$4.20 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.33)($0.32)$3.16 million$2.83 millionViewListenView Earnings Details
11/7/2016Q3($0.31)($0.33)$1.71 million$2.10 millionViewListenView Earnings Details
8/9/2016Q2($0.33)($0.40)$0.17 millionViewN/AView Earnings Details
5/3/2016Q1($0.34)($0.35)ViewListenView Earnings Details
2/26/2016Q4 2015($0.31)($0.35)ViewN/AView Earnings Details
11/3/2015Q3($0.25)($0.32)ViewN/AView Earnings Details
8/5/2015Q215($0.24)($0.26)ViewN/AView Earnings Details
5/5/2015Q115($0.14)($0.25)$0.50 millionViewN/AView Earnings Details
3/3/2015Q414($0.18)($0.24)$0.48 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.21)($0.22)$1.00 million$0.29 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.24)($0.23)$0.48 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.23)($0.25)$0.20 million$0.46 millionViewN/AView Earnings Details
3/3/2014Q4 13($0.32)($0.22)$0.32 millionViewN/AView Earnings Details
11/11/2013Q3($0.32)($0.29)$0.04 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.35)($0.31)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.30)($0.34)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.36)($0.23)ViewN/AView Earnings Details
11/5/2012Q312($0.24)($0.31)$8.82 million$5.80 millionViewN/AView Earnings Details
8/7/2012Q2 2012($0.23)($0.20)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.34)($0.28)ViewN/AView Earnings Details
2/13/2012Q4 2011($0.37)$0.23ViewN/AView Earnings Details
11/1/2011Q3 2011($0.33)($0.38)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.32)($0.31)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.35)($0.29)ViewN/AView Earnings Details
2/14/2011Q4 2010($0.15)($0.45)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.49)($0.48)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.53)($0.41)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.57)($0.54)ViewN/AView Earnings Details
2/16/2010Q4 2009($0.59)$1.45ViewN/AView Earnings Details
10/29/2009Q3 2009($0.71)($0.59)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.63)($0.60)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.60)($0.55)ViewN/AView Earnings Details
2/5/2009Q4 2008($0.54)($0.63)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.44)($0.36)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.45)($0.41)ViewN/AView Earnings Details
5/13/2008Q1 2008($0.39)($0.35)ViewN/AView Earnings Details
1/29/2008Q4 2007($0.35)($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Amicus Therapeutics (NASDAQ:FOLD) Earnings Estimates

2018 EPS Consensus Estimate: ($1.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.32)($0.32)($0.32)
Q2 20181($0.32)($0.32)($0.32)
Q3 20181($0.32)($0.32)($0.32)
Q4 20181($0.32)($0.32)($0.32)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Amicus Therapeutics (NASDAQ:FOLD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Amicus Therapeutics (NASDAQ FOLD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%
Insider Trades by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ FOLD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/23/2018Jay BarthInsiderSell20,000$16.80$336,000.00105,409View SEC Filing  
1/22/2018Bradley L CampbellCOOSell32,500$15.92$517,400.00186,600View SEC Filing  
1/2/2018Daphne QuimiSVPSell8,000$14.72$117,760.0062,676View SEC Filing  
1/2/2018Donald J Hayden JrDirectorSell20,000$15.00$300,000.0025,814View SEC Filing  
1/2/2018Jay BarthInsiderSell5,000$14.71$73,550.0069,184View SEC Filing  
1/2/2018William D Baird IIICFOSell10,000$14.72$147,200.00105,121View SEC Filing  
12/29/2017John F CrowleyCEOSell18,970$14.75$279,807.50View SEC Filing  
12/29/2017John F CrowleyCEOSell5,920$14.75$87,320.00341,051View SEC Filing  
12/21/2017John F CrowleyCEOSell65,581$13.51$885,999.31393,076View SEC Filing  
12/11/2017John F CrowleyCEOSell12,206$13.52$165,025.12340,207View SEC Filing  
12/4/2017John F CrowleyCEOSell47,213$13.61$642,568.93375,214View SEC Filing  
12/1/2017Jay BarthInsiderSell5,000$13.59$67,950.0069,184View SEC Filing  
10/18/2017John F CrowleyCEOSell71,735$14.75$1,058,091.25380,723View SEC Filing  
10/16/2017John F CrowleyCEOSell449,295$14.33$6,438,397.35380,723View SEC Filing  
10/12/2017Daphne QuimiSVPSell7,000$14.25$99,750.00View SEC Filing  
10/12/2017Hung DoInsiderSell50,194$14.25$715,264.50View SEC Filing  
10/12/2017Michael RaabDirectorSell10,000$14.25$142,500.00View SEC Filing  
10/12/2017William D Baird IIICFOSell40,000$14.25$570,000.00View SEC Filing  
9/26/2017John F CrowleyCEOBuy1,395$14.36$20,032.20328,001View SEC Filing  
7/13/2017Life Sciences Maste PerceptiveMajor ShareholderBuy1,500,000$12.25$18,375,000.00View SEC Filing  
6/19/2017Jay BarthInsiderSell30,000$10.00$300,000.0064,184View SEC Filing  
5/19/2017Hung DoInsiderSell29,914$8.00$239,312.00474,438View SEC Filing  
3/2/2017Bradley L CampbellCOOSell49,050$8.00$392,400.00127,475View SEC Filing  
1/13/2017Hung DoInsiderSell25,000$6.00$150,000.00559,266View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$4.96$469,960.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy142,125$4.87$692,148.75View SEC Filing  
12/23/2016Perceptive Advisors LlcMajor ShareholderBuy85,275$4.81$410,172.75View SEC Filing  
12/22/2016Perceptive Advisors LlcMajor ShareholderBuy189,500$4.51$854,645.00View SEC Filing  
11/9/2016Daphne QuimiSVPSell8,546$8.00$68,368.0024,189View SEC Filing  
11/1/2016Hung DoInsiderSell25,000$7.00$175,000.00533,453View SEC Filing  
10/3/2016Hung DoInsiderSell25,000$7.25$181,250.00558,453View SEC Filing  
9/20/2016William D Baird IIICFOSell20,500$8.00$164,000.0056,450View SEC Filing  
9/6/2016Hung DoInsiderSell25,000$7.00$175,000.00583,453View SEC Filing  
8/25/2016Perceptive Advisors LlcInsiderSell1,100,000$6.81$7,491,000.00View SEC Filing  
8/4/2016Jay BarthInsiderSell10,458$7.00$73,206.0015,000View SEC Filing  
7/27/2016Jay BarthInsiderSell20,916$7.00$146,412.0025,458View SEC Filing  
6/2/2016Ellen RosenbergGeneral CounselBuy15,000$7.67$115,050.00View SEC Filing  
11/10/2015Margaret G McglynnDirectorBuy10,000$10.27$102,700.0010,000View SEC Filing  
10/7/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.27$313,500.00View SEC Filing  
10/6/2015Perceptive Advisors LlcMajor ShareholderBuy750,000$6.71$5,032,500.00View SEC Filing  
10/1/2015Kenneth PeistVPSell10,000$13.14$131,400.003,187View SEC Filing  
9/21/2015Bradley L. CampbellCOOSell13,001$16.78$218,156.78156,575View SEC Filing  
9/21/2015William D. Baird IIICFOSell15,236$16.78$255,660.0856,575View SEC Filing  
9/15/2015Hung DoInsiderSell25,000$17.75$443,750.00720,953View SEC Filing  
9/14/2015Daphne QuimiVPSell2,500$18.08$45,200.005,688View SEC Filing  
7/16/2015John F CrowleyCEOSell16,025$16.00$256,400.00View SEC Filing  
7/14/2015John F CrowleyCEOSell142,250$15.03$2,138,017.50View SEC Filing  
7/13/2015Glenn SblendorioDirectorSell10,000$15.00$150,000.00View SEC Filing  
7/13/2015John F CrowleyCEOSell7,750$15.01$116,327.50View SEC Filing  
7/13/2015Ken ValenzanoSVPSell15,000$15.00$225,000.00View SEC Filing  
7/8/2015Dipal DoshiSVPSell6,250$13.87$86,687.50View SEC Filing  
7/1/2015Jayne GershkowitzSVPSell10,649$13.97$148,766.53View SEC Filing  
7/1/2015Kenneth PeistVPSell10,000$13.98$139,800.00View SEC Filing  
6/23/2015Donald J Hayden JrDirectorSell55,000$14.01$770,550.00View SEC Filing  
6/22/2015Jeff CastelliSVPSell18,981$13.94$264,595.14View SEC Filing  
6/19/2015Bradley L CampbellCOOSell13,000$13.26$172,380.00View SEC Filing  
6/19/2015Enrique DiloneSVPSell14,045$13.26$186,236.70View SEC Filing  
6/19/2015William D Baird IIICFOSell15,235$13.26$202,016.10View SEC Filing  
6/15/2015Jeff CastelliSVPSell7,377$14.17$104,532.09View SEC Filing  
6/15/2015Julie YuVPSell8,195$14.17$116,123.15View SEC Filing  
6/8/2015Jeff CastelliSVPSell17,312$12.87$222,805.44View SEC Filing  
6/8/2015John F CrowleyCEOSell55,000$13.01$715,550.00View SEC Filing  
5/11/2015Jeff CastelliSVPSell10,000$10.84$108,400.00View SEC Filing  
5/11/2015Kenneth PeistVPSell12,500$10.84$135,500.00View SEC Filing  
5/11/2015William D Baird IIICFOSell24,800$10.84$268,832.00View SEC Filing  
4/15/2015Glenn SblendorioDirectorSell20,000$12.50$250,000.00View SEC Filing  
4/15/2015Ken ValenzanoVPSell5,000$12.50$62,500.00View SEC Filing  
4/10/2015John F CrowleyCEOSell11,678$12.00$140,136.00View SEC Filing  
4/1/2015Jeff CastelliVPSell9,489$10.69$101,437.41View SEC Filing  
1/5/2015Jeff CastelliVPSell4,667$9.00$42,003.00View SEC Filing  
12/4/2014John F CrowleyCEOSell89,000$8.36$744,040.00View SEC Filing  
11/25/2014Bradley L CampbellCOOSell7,250$8.00$58,000.00View SEC Filing  
11/25/2014Jeff CastelliVPSell8,103$8.00$64,824.00View SEC Filing  
11/25/2014William D Baird IIICFOSell10,000$8.00$80,000.00View SEC Filing  
11/19/2014Perceptive Advisors LlcMajor ShareholderBuy2,100,000$6.50$13,650,000.00View SEC Filing  
10/27/2014Plc GlaxosmithklineMajor ShareholderSell11,315,825$5.29$59,860,714.25View SEC Filing  
10/3/2014Jeff CastelliVPSell8,552$7.00$59,864.00View SEC Filing  
10/3/2014William D Baird IIICFOSell10,000$7.00$70,000.00View SEC Filing  
10/2/2014Julie YuVPSell4,759$5.99$28,506.41View SEC Filing  
9/29/2014Daphne QuimiVPSell10,738$6.10$65,501.80View SEC Filing  
9/29/2014William D Baird IIICFOSell25,311$6.09$154,143.99View SEC Filing  
8/27/2014Glenn SblendorioDirectorSell10,000$6.50$65,000.00View SEC Filing  
8/27/2014Jayne GershkowitzVPSell5,000$7.00$35,000.00View SEC Filing  
8/25/2014Bradley L CampbellCOOSell7,000$6.00$42,000.00View SEC Filing  
8/25/2014Jayne GershkowitzVPSell5,000$6.00$30,000.00View SEC Filing  
8/20/2014Bradley L CampbellCOOSell18,750$5.40$101,250.00View SEC Filing  
8/20/2014Enrique DiloneVPSell12,810$5.40$69,174.00View SEC Filing  
6/30/2014Perceptive Advisors LlcMajor ShareholderBuy4,000,000$3.50$14,000,000.00View SEC Filing  
11/20/2013Plc Glaxosmithklinemajor shareholderBuy1,500,000$2.00$3,000,000.00View SEC Filing  
3/15/2013Sol J BarerDirectorBuy25,000$3.40$85,000.00View SEC Filing  
11/13/2012Joan WinterbottomSVPBuy1,665$4.54$7,559.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amicus Therapeutics (NASDAQ FOLD) News Headlines

Source:
DateHeadline
Amicus Therapeutics, Inc. (FOLD) Receives Consensus Rating of "Buy" from BrokeragesAmicus Therapeutics, Inc. (FOLD) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 24 at 3:40 AM
Amicus Therapeutics (FOLD) Downgraded by Zacks Investment ResearchAmicus Therapeutics (FOLD) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 22 at 10:58 PM
$14.50 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter$14.50 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter
www.americanbankingnews.com - February 22 at 9:44 AM
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock - GlobeNewswire (press release)Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - February 22 at 8:00 AM
Amicus Therapeutics Announces Closing of Underwritten Offering of Common StockAmicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
finance.yahoo.com - February 21 at 5:40 PM
Amicus Therapeutics to Announce Full-Year 2017 Financial Results on February 28, 2018Amicus Therapeutics to Announce Full-Year 2017 Financial Results on February 28, 2018
finance.yahoo.com - February 21 at 8:36 AM
Traders Purchase High Volume of Call Options on Amicus Therapeutics (FOLD)Traders Purchase High Volume of Call Options on Amicus Therapeutics (FOLD)
www.americanbankingnews.com - February 20 at 6:56 AM
Amicus Therapeutics (FOLD) Set to Announce Earnings on TuesdayAmicus Therapeutics (FOLD) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - February 20 at 3:46 AM
Amicus Therapeutics (FOLD) Downgraded by BidaskClub to HoldAmicus Therapeutics (FOLD) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - February 19 at 3:56 PM
Amicus Therapeutics Prices Underwritten Offering of Common StockAmicus Therapeutics Prices Underwritten Offering of Common Stock
finance.yahoo.com - February 16 at 8:01 AM
FY2017 Earnings Estimate for Amicus Therapeutics, Inc. Issued By Leerink Swann (FOLD)FY2017 Earnings Estimate for Amicus Therapeutics, Inc. Issued By Leerink Swann (FOLD)
www.americanbankingnews.com - February 15 at 7:56 AM
Amicus Therapeutics Announces Public Offering of Common StockAmicus Therapeutics Announces Public Offering of Common Stock
finance.yahoo.com - February 15 at 7:34 AM
Amicus Therapeutics (FOLD) Says FDA Filed NDA Under Priority Review for Migalastat for Treatment of Fabry Disease - StreetInsider.comAmicus Therapeutics (FOLD) Says FDA Filed NDA Under Priority Review for Migalastat for Treatment of Fabry Disease - StreetInsider.com
www.streetinsider.com - February 14 at 3:34 PM
Amicus Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference - GlobeNewswire (press release)Amicus Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - February 14 at 7:37 AM
Amicus Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare ConferenceAmicus Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 14 at 7:37 AM
Amicus Therapeutics: Positive Data For Pompe Disease And Recent Regulatory Developments - Seeking AlphaAmicus Therapeutics: Positive Data For Pompe Disease And Recent Regulatory Developments - Seeking Alpha
seekingalpha.com - February 13 at 3:30 PM
BRIEF-U.S. FDA Files NDA Under Priority Review For MigalastatBRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat
www.reuters.com - February 12 at 3:31 PM
U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry DiseaseU.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
finance.yahoo.com - February 12 at 3:31 PM
Research Analysts Issue Forecasts for Amicus Therapeutics, Inc.s Q1 2018 Earnings (FOLD)Research Analysts Issue Forecasts for Amicus Therapeutics, Inc.'s Q1 2018 Earnings (FOLD)
www.americanbankingnews.com - February 12 at 2:34 AM
Amicus Therapeutics, Inc. (FOLD) Sees Large Drop in Short InterestAmicus Therapeutics, Inc. (FOLD) Sees Large Drop in Short Interest
www.americanbankingnews.com - February 10 at 2:02 AM
Robert W. Baird Analysts Give Amicus Therapeutics (FOLD) a $20.00 Price TargetRobert W. Baird Analysts Give Amicus Therapeutics (FOLD) a $20.00 Price Target
www.americanbankingnews.com - February 8 at 8:54 PM
Amicus Therapeutics (FOLD) Price Target Increased to $24.00 by Analysts at Leerink SwannAmicus Therapeutics (FOLD) Price Target Increased to $24.00 by Analysts at Leerink Swann
www.americanbankingnews.com - February 8 at 12:56 PM
Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual ... - GlobeNewswire (press release)Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 7:22 AM
Amicus Therapeutics: Pompe Data Strengthens Bullish Thesis - Seeking AlphaAmicus Therapeutics: Pompe Data Strengthens Bullish Thesis - Seeking Alpha
seekingalpha.com - February 8 at 7:22 AM
Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium™Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium™
finance.yahoo.com - February 8 at 7:22 AM
$14.56 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter$14.56 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter
www.americanbankingnews.com - February 5 at 5:48 AM
 Brokerages Expect Amicus Therapeutics, Inc. (FOLD) Will Post Earnings of -$0.30 Per Share Brokerages Expect Amicus Therapeutics, Inc. (FOLD) Will Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - February 3 at 11:45 AM
Amicus Therapeutics (FOLD) Announces Canadian Drug Expert Committee Grants Positive Recommendation for ... - StreetInsider.comAmicus Therapeutics (FOLD) Announces Canadian Drug Expert Committee Grants Positive Recommendation for ... - StreetInsider.com
www.streetinsider.com - January 30 at 7:25 AM
Amicus Therapeutics, Inc. (FOLD) Given Consensus Rating of "Buy" by BrokeragesAmicus Therapeutics, Inc. (FOLD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 30 at 3:28 AM
Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold™ (migalastat) for Fabry Disease in CanadaCanadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold™ (migalastat) for Fabry Disease in Canada
finance.yahoo.com - January 29 at 7:34 AM
Amicus Therapeutics, Inc. (FOLD) Insider Sells $336,000.00 in StockAmicus Therapeutics, Inc. (FOLD) Insider Sells $336,000.00 in Stock
www.americanbankingnews.com - January 25 at 9:28 PM
Amicus Therapeutics: What To Expect In 2018 - Seeking AlphaAmicus Therapeutics: What To Expect In 2018 - Seeking Alpha
seekingalpha.com - January 25 at 3:31 PM
Insider Selling: Amicus Therapeutics, Inc. (FOLD) COO Sells 32,500 Shares of StockInsider Selling: Amicus Therapeutics, Inc. (FOLD) COO Sells 32,500 Shares of Stock
www.americanbankingnews.com - January 24 at 6:50 PM
Amicus Therapeutics Announces Presentations and Posters at 14th Annual WORLDSymposium™ 2018 - GlobeNewswire (press release)Amicus Therapeutics Announces Presentations and Posters at 14th Annual WORLDSymposium™ 2018 - GlobeNewswire (press release)
globenewswire.com - January 24 at 5:32 AM
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in SpainAmicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Spain
finance.yahoo.com - January 17 at 5:26 PM
Zacks: Brokerages Anticipate Amicus Therapeutics, Inc. (FOLD) Will Announce Earnings of -$0.30 Per ShareZacks: Brokerages Anticipate Amicus Therapeutics, Inc. (FOLD) Will Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - January 17 at 9:56 AM
Head to Head Review: Amicus Therapeutics (FOLD) vs. Dr.Reddy's Laboratories (RDY)Head to Head Review: Amicus Therapeutics (FOLD) vs. Dr.Reddy's Laboratories (RDY)
www.americanbankingnews.com - January 17 at 3:12 AM
Amicus Therapeutics (FOLD) Rating Increased to Buy at BidaskClubAmicus Therapeutics (FOLD) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - January 15 at 11:08 PM
March 2nd Options Now Available For Amicus Therapeutics (FOLD)March 2nd Options Now Available For Amicus Therapeutics (FOLD)
www.nasdaq.com - January 11 at 5:25 PM
Cowen Reaffirms "Buy" Rating for Amicus Therapeutics (FOLD)Cowen Reaffirms "Buy" Rating for Amicus Therapeutics (FOLD)
www.americanbankingnews.com - January 10 at 8:28 PM
Juniper Pharmaceuticals (JNP) versus Amicus Therapeutics (FOLD) Head-To-Head SurveyJuniper Pharmaceuticals (JNP) versus Amicus Therapeutics (FOLD) Head-To-Head Survey
www.americanbankingnews.com - January 10 at 3:28 PM
Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial GuidanceAmicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance
finance.yahoo.com - January 8 at 9:57 AM
Amicus Therapeutics Sees Unusually Large Options Volume (FOLD)Amicus Therapeutics Sees Unusually Large Options Volume (FOLD)
www.americanbankingnews.com - January 6 at 3:12 AM
Traders Buy Large Volume of Amicus Therapeutics Put Options (FOLD)Traders Buy Large Volume of Amicus Therapeutics Put Options (FOLD)
www.americanbankingnews.com - January 6 at 2:08 AM
Amicus Therapeutics, Inc. (FOLD) Receives Average Recommendation of "Buy" from BrokeragesAmicus Therapeutics, Inc. (FOLD) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 5 at 3:38 AM
Jay Barth Sells 5,000 Shares of Amicus Therapeutics, Inc. (FOLD) StockJay Barth Sells 5,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock
www.americanbankingnews.com - January 4 at 8:32 PM
William D. Baird III Sells 10,000 Shares of Amicus Therapeutics, Inc. (FOLD) StockWilliam D. Baird III Sells 10,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock
www.americanbankingnews.com - January 4 at 8:26 PM
Amicus Therapeutics, Inc. (FOLD) SVP Daphne Quimi Sells 8,000 SharesAmicus Therapeutics, Inc. (FOLD) SVP Daphne Quimi Sells 8,000 Shares
www.americanbankingnews.com - January 4 at 8:26 PM
Amicus Therapeutics, Inc. (FOLD) Director Sells $300,000.00 in StockAmicus Therapeutics, Inc. (FOLD) Director Sells $300,000.00 in Stock
www.americanbankingnews.com - January 4 at 7:56 PM
John F. Crowley Sells 5,920 Shares of Amicus Therapeutics, Inc. (FOLD) StockJohn F. Crowley Sells 5,920 Shares of Amicus Therapeutics, Inc. (FOLD) Stock
www.americanbankingnews.com - January 2 at 7:32 PM

SEC Filings

Amicus Therapeutics (NASDAQ:FOLD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amicus Therapeutics (NASDAQ:FOLD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amicus Therapeutics (NASDAQ FOLD) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.